A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with relapsed AML following a short initial complete remission

Giles, FJ; Ferrant, Augustin; Karp, J; Feldman, E; Daenen, S; Bilgrami, SFA; Cahill, A; Vey, N

A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with relapsed AML following a short initial complete remission

Giles, FJ

;

Ferrant, Augustin

;

Karp, J

;

Feldman, E

;

Vey, N

;et.al.

(2006) 46th Annual Scientific Meetign of the British-Society-for-Haematology — Location: Edinburgh (England) (3.April.2006)

Files

No attached file found for this publication.

Details

Authors

Giles, FJ
Author
Ferrant, AugustinUCLouvain
Author
Karp, J
Author
Feldman, E
Author
Vey, N
Author

Affiliations

UCLouvainCliniques universitaires Saint-Luc
UCLouvain

Citations

APA
Chicago
FWB

Giles, F., Ferrant, A., Karp, J., Feldman, E., Daenen, S., Bilgrami, S., Cahill, A., & Vey, N. (2006). A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with relapsed AML following a short initial complete remission. British Journal of Haematology, 133, 64. https://hdl.handle.net/2078.5/140174 (Original work published 2006)